Clinical Trials on AMPD in New Zealand

Total 23 results

Pfenex, Inc

Completed

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

Age Related Macular Degeneration (AMD)

New Zealand
VisionCare, Inc.

Enrolling by invitation

Post-Approval Study of the Implantable Miniature Telescope (PAS-01)

AMD

United States
Vitreous -Retina- Macula Consultants of New York

Completed

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Age-related Macular Degeneration (AMD)

United States
Tyrogenex
International Drug Development Institute; SynteractHCR

Terminated

X-82 to Treat Age-related Macular Degeneration

Eye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Age-Related Macular Degeneration (AMD) | Exudative Age-related Macular Degeneration | AMD | Macular Degeneration, Age-related, 10

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Age-related Macular Degeneration (AMD)

United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)

Age Related Macular Degeneration | CNV | AMD

United States
Regeneron Pharmaceuticals

Completed

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) (RE-VIEW)

Age - Related Macular Degeneration (AMD)

United States
AbbVie

Recruiting

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

CNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMD

United States
AbbVie
AbbVie

Enrolling by invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Gene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMD

United States
StemCells, Inc.

Completed

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

Macular Degeneration | Age Related Macular Degeneration | AMD

United States
PanOptica, Inc.

Completed

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Age-Related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals
Carematix, VAS (Vital Art and Science)

Completed

A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

Age Related Macular Degeneration (AMD)

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Hemoglobinopathies | AML | MDS | Bone Marrow Failure | ALL | Inherited Metabolic Disorders | HLH | MPD Withou Myelofibrosis | NHL or HL

United States
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
AbbVie

Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

CNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMD

United States, Puerto Rico, Canada
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Enrolling by invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study (ORACLE)

Age Related Macular Degeneration (AMD)

United States, Germany, Spain, France, Australia, United Kingdom
Novartis Pharmaceuticals

Completed

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) (FLUID)

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Australia
Genzyme, a Sanofi Company

Completed

Late-Onset Treatment Study Extension Protocol

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)

United States, France, Canada, Netherlands, Australia

Clinical Trials on AMPD in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations